- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07654972
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.
Participation in this study will last about 30 to 39 weeks (7 to 10 months).
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: LillyTrials@Lilly.com
Studera Kontakt Backup
- Namn: Physicians interested in becoming principal investigators please contact
- E-post: clinical_inquiry_hub@lilly.com
Studieorter
-
-
Texas
-
San Antonio, Texas, Förenta staterna, 78232
- Rekrytering
- ICON Early Phase Services, LLC
-
Huvudutredare:
- Cassandra Key
-
Kontakt:
- Telefonnummer: (210) 225-5437
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84124
- Har inte rekryterat ännu
- ICON Early Phase Services, LLC
-
Huvudutredare:
- Ahad Sabet
-
Kontakt:
- Telefonnummer: 801-261-3341
-
-
-
-
-
Singapore, Singapore, 138623
- Har inte rekryterat ännu
- Lilly Centre for Clinical Pharmacology
-
Huvudutredare:
- Jennifer Boon Wee
-
Kontakt:
- Telefonnummer: +65 6413 9811
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
- Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
- Have had a self-reported stable weight for 3 months prior to screening
Exclusion Criteria:
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
- Is an individual of childbearing potential (IOCBP)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A: LY4174794
Participants will receive LY4174794 administered subcutaneously (SC).
|
Administreras SC.
Administered SC.
Administered IV.
|
|
Experimentell: Part B: LY4174794
Participants will receive LY4174794 administered SC.
|
Administreras SC.
Administered SC.
Administered IV.
|
|
Placebo-jämförare: Part A & B: Placebo
Participants will receive placebo administered SC.
|
Administreras SC.
|
|
Experimentell: Part C: LY4174794
Participants will receive LY4174794 administered intravenously (IV).
|
Administered SC.
Administered IV.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsram: Baseline through end of the Follow-up (Week 25)
|
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
|
Baseline through end of the Follow-up (Week 25)
|
|
Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration
Tidsram: Baseline through end of the Follow-up (Week 33)
|
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
|
Baseline through end of the Follow-up (Week 33)
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4174794
Tidsram: Predose on day 1 through end of the Follow-up Period (Week 25)
|
Predose on day 1 through end of the Follow-up Period (Week 25)
|
|
Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794
Tidsram: Predose on day 1 through end of the Follow-up Period (Week 25)
|
Predose on day 1 through end of the Follow-up Period (Week 25)
|
|
Part B: PK: Maximum Observed Drug Concentration (Cmax) of LY4174794
Tidsram: Predose on day 1 through end of the Follow-up Period (Week 33)
|
Predose on day 1 through end of the Follow-up Period (Week 33)
|
|
Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794
Tidsram: Predose on day 1 through end of the Follow-up Period (Week 33)
|
Predose on day 1 through end of the Follow-up Period (Week 33)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 27797
- J6W-MC-YMAA (Annan identifierare: Eli Lilly and Company)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .